David Westenberg
Stock Analyst at Piper Sandler
(4.56)
# 253
Out of 5,147 analysts
197
Total ratings
56.25%
Success rate
22.51%
Average return
Main Sectors:
Stocks Rated by David Westenberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WGS GeneDx Holdings | Maintains: Overweight | $160 → $130 | $79.71 | +63.09% | 4 | Feb 24, 2026 | |
| GH Guardant Health | Maintains: Overweight | $120 → $130 | $93.90 | +38.45% | 11 | Feb 24, 2026 | |
| NEO NeoGenomics | Maintains: Overweight | $12 → $13 | $9.83 | +32.25% | 11 | Feb 24, 2026 | |
| LH Labcorp Holdings | Maintains: Neutral | $270 → $300 | $289.12 | +3.76% | 5 | Feb 24, 2026 | |
| IDXX IDEXX Laboratories | Maintains: Neutral | $775 → $750 | $656.73 | +14.20% | 12 | Feb 9, 2026 | |
| ILMN Illumina | Maintains: Overweight | $195 → $170 | $134.46 | +26.43% | 17 | Feb 9, 2026 | |
| ELAN Elanco Animal Health | Upgrades: Overweight | $24 → $30 | $26.40 | +13.64% | 11 | Jan 22, 2026 | |
| ZTS Zoetis | Downgrades: Neutral | $190 → $135 | $131.10 | +2.97% | 16 | Jan 22, 2026 | |
| NEOG Neogen | Reiterates: Neutral | $6.5 → $10 | $11.23 | -10.95% | 14 | Jan 12, 2026 | |
| BLLN BillionToOne | Initiates: Overweight | $150 | $76.33 | +96.52% | 1 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $19 | $23.05 | -17.57% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $80 | $53.25 | +50.23% | 6 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.5 → $2 | $1.68 | +19.05% | 10 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $220 → $230 | $208.04 | +10.56% | 17 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $21 → $30 | $15.33 | +95.69% | 10 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $80 | $103.38 | -22.62% | 13 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7.5 | $4.48 | +67.41% | 10 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $190 → $200 | $211.91 | -5.62% | 8 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $20 | $16.02 | +24.84% | 15 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $22.74 | - | 2 | Jan 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $26.54 | - | 1 | Nov 21, 2017 |
GeneDx Holdings
Feb 24, 2026
Maintains: Overweight
Price Target: $160 → $130
Current: $79.71
Upside: +63.09%
Guardant Health
Feb 24, 2026
Maintains: Overweight
Price Target: $120 → $130
Current: $93.90
Upside: +38.45%
NeoGenomics
Feb 24, 2026
Maintains: Overweight
Price Target: $12 → $13
Current: $9.83
Upside: +32.25%
Labcorp Holdings
Feb 24, 2026
Maintains: Neutral
Price Target: $270 → $300
Current: $289.12
Upside: +3.76%
IDEXX Laboratories
Feb 9, 2026
Maintains: Neutral
Price Target: $775 → $750
Current: $656.73
Upside: +14.20%
Illumina
Feb 9, 2026
Maintains: Overweight
Price Target: $195 → $170
Current: $134.46
Upside: +26.43%
Elanco Animal Health
Jan 22, 2026
Upgrades: Overweight
Price Target: $24 → $30
Current: $26.40
Upside: +13.64%
Zoetis
Jan 22, 2026
Downgrades: Neutral
Price Target: $190 → $135
Current: $131.10
Upside: +2.97%
Neogen
Jan 12, 2026
Reiterates: Neutral
Price Target: $6.5 → $10
Current: $11.23
Upside: -10.95%
BillionToOne
Dec 1, 2025
Initiates: Overweight
Price Target: $150
Current: $76.33
Upside: +96.52%
Nov 11, 2025
Maintains: Neutral
Price Target: $15 → $19
Current: $23.05
Upside: -17.57%
Nov 11, 2025
Maintains: Neutral
Price Target: $105 → $80
Current: $53.25
Upside: +50.23%
Nov 11, 2025
Maintains: Neutral
Price Target: $1.5 → $2
Current: $1.68
Upside: +19.05%
Nov 11, 2025
Maintains: Overweight
Price Target: $220 → $230
Current: $208.04
Upside: +10.56%
Nov 11, 2025
Maintains: Neutral
Price Target: $21 → $30
Current: $15.33
Upside: +95.69%
Nov 11, 2025
Maintains: Overweight
Price Target: $70 → $80
Current: $103.38
Upside: -22.62%
Nov 11, 2025
Maintains: Overweight
Price Target: $8 → $7.5
Current: $4.48
Upside: +67.41%
Oct 27, 2025
Maintains: Neutral
Price Target: $190 → $200
Current: $211.91
Upside: -5.62%
Oct 15, 2025
Maintains: Overweight
Price Target: $15 → $20
Current: $16.02
Upside: +24.84%
Jan 4, 2018
Upgrades: Buy
Price Target: n/a
Current: $22.74
Upside: -
Nov 21, 2017
Initiates: Neutral
Price Target: n/a
Current: $26.54
Upside: -